Hantz Financial Services Inc. Sells 6,373 Shares of Icon Plc $ICLR

Hantz Financial Services Inc. cut its holdings in shares of Icon Plc (NASDAQ:ICLR) by 23.0% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 21,306 shares of the medical research company’s stock after selling 6,373 shares during the period. Hantz Financial Services Inc.’s holdings in Icon were worth $3,099,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ICLR. Cantillon Capital Management LLC bought a new position in Icon during the second quarter worth about $67,663,000. First Pacific Advisors LP lifted its holdings in Icon by 76.3% during the second quarter. First Pacific Advisors LP now owns 964,120 shares of the medical research company’s stock worth $140,231,000 after acquiring an additional 417,173 shares in the last quarter. Coho Partners Ltd. bought a new position in Icon during the second quarter worth about $33,649,000. Allspring Global Investments Holdings LLC lifted its holdings in Icon by 18.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,060,499 shares of the medical research company’s stock worth $157,887,000 after acquiring an additional 162,853 shares in the last quarter. Finally, Ninety One UK Ltd lifted its holdings in Icon by 2.6% during the second quarter. Ninety One UK Ltd now owns 2,993,652 shares of the medical research company’s stock worth $435,427,000 after acquiring an additional 75,465 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. TD Cowen dropped their price target on Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research note on Friday, October 24th. Cowen reissued a “hold” rating on shares of Icon in a research note on Friday, October 24th. UBS Group set a $220.00 price target on Icon in a research note on Friday, October 24th. Evercore ISI lifted their price target on Icon from $170.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Finally, Barclays dropped their price target on Icon from $190.00 to $185.00 and set an “equal weight” rating on the stock in a research note on Friday, October 24th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $207.14.

Icon Price Performance

NASDAQ:ICLR opened at $171.82 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The stock’s 50-day simple moving average is $178.16 and its 200 day simple moving average is $159.38. The company has a market cap of $13.88 billion, a P/E ratio of 23.25, a P/E/G ratio of 3.04 and a beta of 1.23. Icon Plc has a 52-week low of $125.10 and a 52-week high of $231.89.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, October 22nd. The medical research company reported $3.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.28 by $0.03. The business had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $1.98 billion. Icon had a return on equity of 10.58% and a net margin of 7.40%.Icon’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.35 earnings per share. As a group, sell-side analysts forecast that Icon Plc will post 13.38 EPS for the current fiscal year.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.